echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Good Essay Collection Blood biomarkers in neurology

    Good Essay Collection Blood biomarkers in neurology

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Special Issue on Blood Biomarkers In Neurology

    Issue Edited by: Henrik Zetterberg, Johan Zelano


    REVIEW ARTICLES



    Blood biomarkers of peripheral neuropathy

    Blood biomarkers of peripheral neuropathy

    Alexander M.
    Rossor, Mary M.
    Reilly


    The notion that blood tests could be used to diagnose and monitor peripheral nerve damage has always seemed fanciful, however, with the development of ultrasensitive protein assays, their detection limits are lower than traditional ELISA techniques, allowing markers of nerve damage such as NFL to be accurately measured
    in the blood.
    However, a key obstacle is the inability to distinguish between central and peripheral nerve degeneration
    .
    Nevertheless, these protein biomarkers appear to be effective in identifying patients with peripheral neuropathy compared to controls and have shown effectiveness
    as markers of disease activity in patients with rapidly progressing peripheral neuropathy such as vasculitis and amyloidosis.
    The use of axonal protein biomarkers such as NFL in slowly progressive diseases without significant axon loss (e.
    g.
    , CMT, CIDP, and multifocal motor neuropathy) is uncertain
    .
    Measurements of correlated circulating microRNAs show great promise because quantification techniques are well established to select specific microRNAs
    specific to disease processes.


    Article Links:

    https://onlinelibrary.
    wiley.
    com/doi/10.
    1111/ane.
    13650


    Scan the code to quickly get the full text




    Blood based biomarkers for movement disorders

    Blood biomarkers of dyskinesia

    Huw R.
    Morris


    The development of blood biomarkers for AD, as well as the identification of NfL as a prognostic marker and diagnostic marker for atypical Parkinson's disease, may have a direct impact on patient selection and stratification of clinical trials, which may then be applied to clinical practice
    .
    More natural, long-term studies are likely needed to evaluate the additional role of blood biomarkers beyond standard clinical practice and to directly assess the clinical benefits
    of early diagnosis and more accurate prognosis in everyday practice.
    The gold standard for most diagnostic research remains clinical diagnosis using standard diagnostic criteria, or clinical diagnosis supplemented by PET protein imaging studies, which in my opinion represents a reasonable proof of concept using blood biomarkers, rather than a definitive proof
    of benefit in a routine clinical setting.
    A multimodal approach that combines blood biomarkers with demographics, genetics, imaging, and clinical features has the potential to maximize diagnostic and predictive accuracy
    , in addition to being able to assess the role of biomarkers in a holistic clinical context.


    In addition to AD biomarkers and NfL, the development of specific tau and α-synuclein blood biomarkers for dyskinesia has so far been disappointing, but rapid advances in protein aggregation and high-throughput multiplexing suggest that new biomarker detections, profiles, and profiles will continue to be developed, evaluated, and integrated into protocols for future clinical trials and clinical practice
    .


    Article Links:

    https://onlinelibrary.
    wiley.
    com/doi/10.
    1111/ane.
    13700


    Scan the code to quickly get the full text




    Blood biomarkers in epilepsy

    Blood biomarkers of epilepsy

    Rakesh Kumar Banote, Sarah Akel, Johan Zelano


    In this review, we provide a narrative overview
    of potential blood biomarkers of epilepsy.
    To accelerate the use of these biomarkers in clinical practice, further research
    is needed.
    Advances in this area may require the collection of large well-characterized samples
    from longitudinal studies of well-defined patient cohorts.
    Special efforts should be made to classify
    epilepsy and seizure types in more detail.
    Epilepsy is a very heterogeneous disorder, and it may not be possible to identify biomarkers of epilepsy in a case or in the study of a specific seizure type
    .
    Working together to create common data elements for inclusion in epilepsy blood biomarker studies may increase the likelihood of
    data sharing and subgroup analysis.
    Candidate markers need to be compared between different patient groups (with epilepsy vs no epilepsy, recent seizures vs epileptic, etc.
    ).

    After that, the sensitivity and specificity
    of each clinical application need to be determined.
    Diagnosing blood biomarkers is still a long way off, but the field is moving
    forward.


    Article Links:

    https://onlinelibrary.
    wiley.
    com/doi/10.
    1111/ane.
    13616


    Scan the code to quickly get the full text




    Blood biomarkers in ALS: challenges, applications and novel frontiers

    Blood biomarkers in amyotrophic lateral sclerosis: challenges, applications, and new frontiers

    Ellie Sturmey, Andrea Malaspina


    TDP-43 proteopathy is a typical neuropathological event
    in most patients with amyotrophic lateral sclerosis and some patients with FTD.
    Mislocalization of TDP-43 from the nucleus to the cytoplasm leads to loss of nuclear function, affecting RNA translation of a large number of proteins, including the protein unc-13 homolog a (UNC13A).

    In the case of UNC13A, this results in random inclusion of so-called cryptoexons (derived from non-conserved intron sequences) and the formation of cryptopeptides
    when translated into the final protein.
    UNC13A as a regulator of synaptic function and neurotransmitter release
    .
    In amyotrophic lateral sclerosis (ALS), cryptic exon clathrates in UNC13A, and other loss-of-function TDP-43-controlled proteins may produce abnormal and toxic proteomes
    .
    If there are two single nucleotide polymorphisms (SNPs), rs12973192 and rs12608932, located within or near the exome insertion site, the risk of inclusion of exons in UNC13A increases
    .
    In genome-wide association studies, both have been shown to increase the risk of
    ALS.
    For example, in sporadic ALS patients, rs12608932 SNP is associated with earlier onset in patients with ALS in Europe and the United States, and is associated with shorter survival times and frontotemporal degeneration The loss of UNC13A function leads to a decrease in miR-3911 expression, which is usually detected in neuron-derived extracellular plasma vesicles, Therefore, the detection of miR-3911 downregulation is an alternative to UNC13a-related pathology and can be detected without resorting to expensive whole genome sequencing


    Premature merging of crypteons and formation of abnormal proteins, as indicated by other proteins downstream of UNC13A and TDP-43 loss of function, may be a decisive pathological event
    in amyotrophic myelosis.
    It may constitute a paradigm shift in biomarker research for this neurodegenerative disease, especially since TDP-43 pathology is largely ALS/
    ftd-specific.
    Therefore, cryptopeptide formation is a potential source of biomarkers for early diagnosis and stratification
    of specific endophenotypes in ALS patients.
    Loss of normal function and cryptoexon inclusion of UNC13A can also be used as pharmacological biomarkers for future therapeutic interventions aimed at preventing the formation
    of amyotrophic lateral sclerosis cryptopeptides.
    NFS undoubtedly shapes the outlook for neurodegenerative disease disease surveillance and contributes to the prognostic features of amyotrophic lateral sclerosis, and the discovery of amyotrophic lateral sclerosis cryptoproteins may provide the basis
    for the next generation of biomarkers for this incurable disease.


    Article Links:

    https://onlinelibrary.
    wiley.
    com/doi/10.
    1111/ane.
    13698


    Scan the code to quickly get the full text




    Fluid biomarkers in stroke: From animal models to clinical care

    Liquid biomarkers of stroke: from animal models to clinical care

    Alexandre Dias, Lénia Silva, João Moura, Denis Gabriel, Luis F.
    Maia


    Stroke is the leading cause of
    death and disability worldwide.
    Stroke prevention, early diagnosis and effective acute treatment are priorities
    that successfully influence stroke death and disability.
    Liquid biomarkers improve the differential diagnosis of stroke, stratification of patients for acute care, and individualized rehabilitation
    after stroke.
    In our current work, we describe the application of stroke animal models to fluid biomarker studies through a systematic review of the PubMed and Scopus databases, and then review the literature translating it into human stroke care settings and future prospects
    in the field.
    We found an increasing number of publications, but limited
    clinical translations.
    Animal studies are very heterogeneous and cannot explain the few human traits that appear in stroke, and, importantly, only a few such studies use human cohorts to validate biomarker findings
    .
    Clinical studies have identified attractive candidate substances, including proteins and circulating nucleic acids, that could help shape a more personalized approach to
    stroke care.
    Nevertheless, the complexity of brain tissue and the fact that different brain pathologies share lesion biomarkers make this task challenging due to the low
    specificity of biomarkers.
    In addition, study design and lack of validation cohorts may hinder the formal integration
    of biomarkers in different steps of stroke diagnosis and treatment.
    To overcome these issues, recent critical studies on biomarker dynamics in individual patients provide added value
    for diagnosing and predicting early patient outcomes.
    Currently, the most consistent protein biomarkers for stroke diagnosis and short- and long-term prognosis are associated
    with tissue damage at neuronal (TAU), axon (NFL), or astroglial (GFAP and S100β) levels.
    Most promising nucleic acids are microRNAs (miR) because of their stability and ease of availability
    in plasma.
    Still, clinical validation and standardized quantification put them one step
    behind comparative proteins as stroke biomarkers.
    Ultimately, the definition of clinically relevant biomarker panels and the optimization of rapid, sensitive biomarker measurements in blood, combined with clinical and neuroimaging data, will pave the way for
    personalized stroke care.


    Article Links:

    https://onlinelibrary.
    wiley.
    com/doi/10.
    1111/ane.
    13668


    Scan the code to quickly get the full text




    Wiley is a global leader in research and education, unleashing human potential
    by promoting discovery, empowering education and shaping talent.
    For more than 200 years, Wiley has driven the development of
    the global knowledge ecosystem.
    Today, our high-impact content, platforms and services help researchers, learners, institutions and businesses achieve their goals
    in a rapidly changing world.
    Wiley's global headquarters is located in Hoboken, New Jersey, USA, and the company is listed on the New York Stock Exchange under the symbols WLY and WLYB
    .


    Like, watch, share, let's have a one-click triple!


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.